NASDAQ : ZBIO

Zenas BioPharma, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 28.76 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.87B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Details

NameZenas BioPharma, Inc.
SectorHealthcare
IndustryBiotechnology
Employees167
Founded2019
Ipo Date2024-09-13
CeoLeon Moulder
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price17.00
IsinUS98937L1052
Cusip98937L105
Cik1953926
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Leon Oliver Moulder Jr., M.B.A.Founder, Chief Executive Officer and Chairman
Joseph L. FarmerChief Operating Officer, President, Principal Financial Officer and Principal Accounting Officer
Dr. Lisa von Moltke M.D.Head of Research and Development and Chief Medical Officer
Dr. Heinrich Schlieker Ph.D.Chief Technical Officer
Dr. Haley Laken Ph.D.Chief Scientific Officer
Caroline ChevalierChief Administrative Officer

Contact

Address852 Winter Street, Suite 250, Waltham, Massachusetts 02451, United States
Phone857 271 2954
Websitehttps://zenasbio.com